Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunil Sharma

Showing results (411-420 of 429) with videos related to

Pageof 43
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2012
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelinesAl B Benson, J Pablo Arnoletti, Tanios Bekaii-Saab, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2012
Rectal cancerAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2013
Metastatic colon cancer, version 3.2013: featured updates to the NCCN GuidelinesAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Localized colon cancer, version 3.2013: featured updates to the NCCN GuidelinesAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in OncologyAl B Benson, Alan P Venook, Lynette Cederquist, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Colon cancer, version 3.2014Al B Benson, Alan P Venook, Tanios Bekaii-Saab, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Rectal Cancer, Version 2.2015Al B Benson, Alan P Venook, Tanios Bekaii-Saab, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 15, 2018
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyAl B Benson, Alan P Venook, Mahmoud M Al-Hawary, et al.
Pageof 43

Showing results (411-420 of 429) with videos related to

Sort By:
Pageof 43
Journal of the National Comprehensive Cancer Network : JNCCN|April 12, 2012
Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelinesAl B Benson, J Pablo Arnoletti, Tanios Bekaii-Saab, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 11, 2012
Rectal cancerAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 16, 2013
Metastatic colon cancer, version 3.2013: featured updates to the NCCN GuidelinesAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2013
Localized colon cancer, version 3.2013: featured updates to the NCCN GuidelinesAl B Benson, Tanios Bekaii-Saab, Emily Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 10, 2017
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in OncologyAl B Benson, Alan P Venook, Lynette Cederquist, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Colon cancer, version 3.2014Al B Benson, Alan P Venook, Tanios Bekaii-Saab, et al.
Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Cancer Discovery|October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaRichard D Kim, Debashis Sarker, Tim Meyer, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 19, 2015
Rectal Cancer, Version 2.2015Al B Benson, Alan P Venook, Tanios Bekaii-Saab, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 15, 2018
Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in OncologyAl B Benson, Alan P Venook, Mahmoud M Al-Hawary, et al.
Pageof 43